Skip to content

Core Outcome Set for Rosacea




Rosacea is an extremely common multisystem inflammatory disorder that includes cutaneous and ocular manifestations.  Apart from being disfiguring and socially embarrassing due to erythema, flushing, skin hypertrophy, and visible blood vessels, rosacea can be uncomfortable and painful.  The range of possible treatments for cutaneous rosacea includes anti-inflammatory and antimicrobial agents, medications to reduce hyperemia, and vascular lasers and lights.  Since research on more effective treatments for rosacea remains an active area of study, the development of a core outcome set for rosacea would be particularly useful for facilitating comparison of therapeutic modalities.

Scope of the intended COS

  • Study types: e.g. RCTs: RCTs or Controlled Clinical Trials
  • Region, e.g. global scope: Global scope


We aim to develop a core outcome set by (1) identifying all current outcomes from a systematic review of literature; (2) involving other stakeholder groups such as other clinicians, and regulators to participate in identifying additional outcomes; (3) conducting Delphi consensus exercises on the identified outcomes; (4) presenting all results from the Delphi exercises during a face-to-face (if possible) consensus meeting to vote and agree upon a core set of outcomes important for rosacea research.

Involvement of stakeholders

Stakeholders, or those invested in the development of a core outcome set, will also be included in the decision process, along with patients. Dermatologists, and industry scientists associated treatments for rosacea are potential members that can provide input regarding what outcomes they feel should be represented. Nurses, physician assistants, and other health care practitioners may be included as well to enhance further discussion.

Current status

  • Published protocol and completed a systematic review of literature.


Departmental research funds

Involved Countries


Date of updates

  • 10/08/2020


  • Murad Alam, MD

Project team members

Steering Committee:

  • Murad Alam, MD
  • Joseph F. Sobanko, MD
  • Ian A. Maher, MD
  • Todd V. Cartee, MD

Responsible member of Methods group (as assigned by CS-COUSIN)

  • Jamie Kirkham, PhD


Murad Alam, MD (

Published references

  1. Iyengar S, Williamson PR, Schmitt J, Johannsen L, Maher IA, Sobanko JF, Cartee TV, Schlessinger D, Poon E, Alam M. Development of a core outcome set for clinical trials in rosacea: study protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey. Trials. Sep 1 2016;17doi:ARTN 429 10.1186/s13063-016-1554-3